GIOACCHINO NATOLI, M.D.

Curriculum vitae

ORCID ID: 0000-0003-0711-2411

SCOPUS ID: 7006129365

PRESENT POSITION and ADDRESS

Group Leader
Department of Experimental Oncology
European Institute of Oncology (IEO)
Milan

DEGREE

Medical Doctor with honors, University of Rome, La Sapienza (24/7/1991). Thesis title: *Activation of cellular proto-oncogenes by the Hepatitis B Virus X protein and its role in the pathogenesis of hepato-cellular carcinoma*.

EDUCATION

1991-October 1997	Residency in Internal Medicine (1st Post-graduate School of Internal Medicine, Univ. of Rome, La Sapienza).
1985-1991	Univ. of Rome, La Sapienza, School of Medicine.

RESEARCH TRAINING

1998-June 2000	Post-doctoral fellow in the Laboratory of Molecular Biology and Transcriptional Regulation, Dept. of Pharmacology, UCSD (Prof. Michael Karin)
1991-1997	Graduate student in the Laboratory of Genetic Expression, Institute of I Clinica Medica, Univ. of Rome, La Sapienza (Prof. Massimo Levrero).
1986-1990	Undergraduate Student in the Institute of Histology of the Univ. of Rome La Sapienza (Prof. Michela Galdieri).

RESEARCH AND PROFESSIONAL EXPERIENCE

2020-present
Group Leader, European Institute of Oncology (IEO), Milan, Italy

July 2016-2019:
Full Professor of Biochemistry, School of Medicine, Humanitas University, Milan

September 2005-2016:
Group Leader, European Institute of Oncology (IEO), Milan, Italy

June 2000-August 2005:
Group Leader, Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland

CURRENT AND PAST RESEARCH TOPICS

Control of gene expression in innate immune responses and in macrophage differentiation. Transcriptional control and chromatin biology. Molecular biology of pancreatic cancer. Signaling through receptors for bacterial components and cytokines. Viral hepatitis and hepatocellular carcinoma.

MAIN AWARDS AND GRANTS

2020-2022	*Highly cited researcher* in Immunology (Clarivate)
2017	*Elected member of the Academia Europaea*
2016-2021	*European Research Council (ERC)* Advanced Grant
2013	*Elected member of the European Molecular Biology Organization (EMBO)*
2011-2015	*European Research Council (ERC)* Advanced Grant
2009	*Chiara D'Onofrio prize* for Italian researchers below 43 y
2007-2010	*Marie Curie Excellence Grant* (European Commission, Framework Program 6)
2005-2008	*Human Frontiers Science Program (HFSP)*, Young Investigator Grant
2003	*Roche Research Foundation*
2002-2006	*Swiss Federation against Cancer*
2001-2005	*Swiss National Science Foundation* (2)
1998-2000	Long Term Fellowship for M.D./Ph.D. from the *Damon Runyon-Walter Winchell Cancer Research Fund*
1991	*Institute Pasteur-Fondazione Cenci Bolognetti* Prize for best graduation thesis in the field of infectious diseases.

OTHER GRANTS

-AIRC (Italian Association for Research on Cancer): 2005-2008; 2008-2011; 2011-2014; 2014-2017; 2017-2022; 2023-)
-EC H-2020: SYSCID (Systems Biology of Chronic Inflammatory diseases; 2017-2022; Consortium grant)
-EC FP7:
MODHEP (Modeling Hepatocellular Carcinoma; 2011-2015; Consortium grant)
ModelIN (Modeling Inflammatory responses; 2008-2011; Consortium grant)
-AICR (Association for International Cancer Research, now Worldwide Cancer Research UK): 2010-2012
-Italian Ministry of Health (Ricerca Finalizzata): 2012-2016
-Italian Ministry of University and Research (Fare Ricerca): 2017-2021)
-Cariplo Foundation: 2017-2020
-Fellowships to group components from: AIRC, Marie Curie-Sklodowska program, Umberto Veronesi Foundation, EMBO

COMMISSIONS OF TRUST (SELECTED)

-2018-2024:	European Research Council (ERC) Consolidator Grants
-2018, 2023	Max Delbruck Center (MDC), Berlin, Scientific Evaluation of the MDC
-2011-2019:	Italian Association for Research on Cancer (AIRC) - Scientific and Technical Committee (CTS)
-2013-2016:	Human Frontiers Science Program (HFSP) - Fellowship Selection Committee
-2009-2016:	Steering Committee of the Structural Genomics Consortium (SGC; Oxford, Stockholm, Toronto) – Epigenetics
-2010, 2017:	ANR (Agence Nationale de la Recherche, France), Evaluation Committee

-2012, 2017: Fundação para a Ciência e a Tecnologia (Portugal), Evaluation Committee
-2009: Chair of the SAB of the GIGA-R Signal Transduction Unit (Lieges, Belgium)

INSTITUTIONAL ACTIVITIES

Member of the Executive Committee, IFOM-IEO Campus (2007-2013)
Chairman of the Recruitment and Career Track Committee, IFOM-IEO Campus (2007-2013)
Chairman of the Management Committee, Department of Experimental Oncology, IEO (2009-2016)
Member of the Office of the Chairman, Department of Experimental Oncology, IEO (2013-2017)

INVITED PRESENTATIONS AT INTERNATIONAL CONFERENCES (selected)

2023 - EMBO Workshop on enhanceropathies, Marseille, France
2023 - Gordon Research Conference, Pancreatic Diseases, Il Ciocco, Italy
2022 - EMBO Workshop on RNA 3' end formation and the regulation of eukaryotic genomes, Oxford, UK
2022 - Gordon Research Conference, Immunochemistry and Immunobiology, Casteldefels, Spain
2022 - EMBO Workshop on The Many Faces of Cancer Evolution, Rimini, Italy
2021 - EMBO Workshop on Enhanceropathies: understanding enhancer function to understand human disease, Santander, Spain
2021 - Keystone symposia, Virtual conference - Innate immunity: mechanisms and regulation
2020 - 14th EMBL Conference on Transcription and Chromatin, Virtual conference
2019 - Future of Immunology @Berlin
2019 - 20th Anniversary FEBS International Summer School on Immunology – Immune System: genes, receptors and regulation, Hvar, Croatia
2019 - Next Gen Immunology in Health and disease, Osaka, Japan
2019 - Keystone symposia, Transcription and RNA regulation in inflammation and immunity, Granlibakken, USA (co-organizer)
2018 - 47th meeting of the Japanese Society of Immunology, Fukuoka, Japan
2018 - Cold Spring Harbor Laboratory, Gene Expression and Signaling in the Immune System, CSH, NY, USA
2018 - Keystone symposia, Regulation and dysregulation of innate immunity in disease, Vancouver, Canada
2018 - 9th German-Israeli Cancer Research School, Grainau, Germany
2017 - Epigenetics and chromosomal topology in differentiation and disease, Montpellier, France
2017 - 50th Anniversary Meeting, Society of Leukocyte Biology (SLB), Vancouver, Canada
2017 - European Macrophage and Dendritic Cell Society (EMDS) Meeting, Madrid, Spain
2017 - Symposium on Cellular Innate Immunity, Freiburg, Germany
2017 - 29th Pezcoller Symposium, Trento, Italy
2017 - AbbVie Myeloid Forum, Chicago, USA
2017 - International Organization of Inflammatory Bowel Diseases (IOIBD), Stresa, Italy
2017 - 37th European Workshop for Rheumatology Research (EWRR), Athens, Greece
2017 - INSERM Workshop 'Enhancer structure and function', Bordeaux, France
2016 - Cancer evolution: Mechanism of vulnerability and resistance, MD Anderson Cancer Center, Houston, TX, USA
2016 - Radboud Summer Frontiers Symposium, Nijmegen, The Netherlands
2016 - Society for Leukocyte Biology (SLB), Annual Meeting, Verona, Italy
2016 - iCORE meeting, Chromatin and RNA in gene regulation, Weizmann Institute of Science, Rehovot, Israel
2016 - Cell Press Conference, 100 years of Phagocytes, Giardini Naxos, Italy
2016 - Gordon Research Conference, Immunochemistry and Immunobiology, Il Ciocco, Italy
2016 - Keystone Symposia, Myeloid Cells, Killarney, Ireland
2016 - Keystone Symposia, Enhancer Malfunction in Cancer, Santa Fe', USA
2015 - European Society of Gene and Cell Therapy, Helsinki, Finland
2015 - Chromatin Symposium 2015, Marburg, Germany
2015 - World Congress of Inflammation, Boston, MA
2015 - Innate Immune Memory Conference, Wellcome Trust Hinxton Campus, Cambridge, UK
2014 - 11th EMBL conference on Transcription and Chromatin, Heidelberg, Germany

2014 - Cold Spring Harbor Laboratory Symposium on Gene Expression and Signaling in the Immune System, Cold Spring Harbor, NY
2014 - Keystone Symposium on Molecular Cell Biology of Macrophages, Santa Fe, USA
2014 - 24th Biocity Symposium, Turku, Finlan
2013 - IHEC (International Human Epigenome Consortium) Science Days, Berlin, Germany
2013 - 35th Annual Sanford-Burnham Symposium, San Diego, USA
2013 - Enhancer function and biology meeting, Stowers Inst., Kansas City, USA
2013 - Single cell genomics meeting, Weizmann Institute, Rehovot, Israel
2013 - 15th International Congress of Immunology, ICI, Milan, Italy
2013 - 10th International Conference on Innate Immunity, Kos, Greece
2013 - 78th Cold Spring Harbor Laboratory Symposium on Quantitative Biology – Immunity and Tolerance, Cold Spring Harbor, NY
2013 - European Association for the Study of Liver, Amsterdam, The Netherlands
2013 - Oxford Epigenetics Symposium – SGC Epysim 2013, Oxford University
2013 - EMBO workshop - Dr Jekyll and Mr Hyde: The Macrophage in Inflammation and Immunity, Marseille, France
2012 - World Epigenetics Summit, London, UK
2012 - 2nd Barcelona Chromatin Club - The Epigenetic Regulation of Cellular Differentiation and Tissue Regeneration, Barcelona, Spain
2012 - Conference on Gene Regulation: from DNA Sequence to Nuclear Structure,cAthens, Greece
2012 - 2nd Conference of Translational Medicine on the Pathogenesis and Therapy of Immune-Mediated Diseases Milan, Italy
2012 - Royal Society discussion meeting - Regulation from a distance: long-range control of gene expression in development and disease, London, UK
2012 - Training the Innate Immunity – Summer Frontiers Symposium, Nijmegen University, The Netherlands
2012 - European Macrophage and Dendritic Cell Society (EMDS) Annual meeting, Debrecen, Hungary
2011 - 12th International Conference on Systems Biology (ICSB) – Heidelberg, Germany
2011 - Cincinnati Cancer Symposium Series - Symposium on NF- κB, Cancer, Obesity, and Inflammation, Cincinnati, OH, USA
2010 - European Macrophage and Dendritic Cell Society, Edinburgh, Scotland
2010 - 10th Advanced Meeting on Cancer Omics, Italy
2010 - Harvard School of Public Health - Symposium Epigenetic Regulation in Health and Disease, Boston, MA, USA
2010 - Keystone Symposium (Santa Fé, USA) - NF-kappaB in Inflammation and Disease
2009 - Immunoepigenetics Symposium, Rockfeller University, New York, USA
2009 - Epigenetic Mechanisms in Health and disease, Toronto, Canada
2009 - EMBO conference - Tackling and Imaging the complexity of the Immune system, Italy
2009 - Nijmegen Medical Center - Symposium Epigenetics and disease, Njmegen, The Netherlands
2008 - Oxford University - Epigenetic Mechanisms in Health and Disease: From Biology to Medicine, Oxford, UK
2008 - NIH Roadmap initiative to the Epigenome - NIDDK meeting on Dynamic Epigenome and Homeostatic Regulations in health and disease, Bethesda, USA
2008 - EMBO workshop - NF-kB network in development and disease, Capri, Italy
2008 - ICT-BIO – EC meeting on Computer modelling and simulation for improving human health Bruxelles, Belgium
2008 - Helmholtz Zentrum - Workshop Mouse models for functional genomics in Immunology", Braunschweig, Germany
2008 - Biophysical Society Meeting, Long Beach, USA
2008 - Keystone Symposium (Banff, Canada) - NF-kappaB in Inflammation and Disease 2006 - Society for Leukocyte Biology, San Antonio, Tx, USA
2006 - FEBS Congress, Istanbul, Turkey
2004 - Keystone Symposium (Snowbird, USA) - NF-kB from bench to bedside
2003 - Keystone Symposium (Keystone resort, USA) - Dendritic cells
2002 - German Society for Immunology, Marburg, Germany
2002 - ENII (European Network of Immunological Institutes) meeting, Iles des Embiez, France
2002 - Juan March Foundation workshop on NF-kB, Madrid, Spain

SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS

2000 – 2005 3 Postdocs / 1 PhD student / 1 Master Student
Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland
2005 – 2021 32 Postdocs / 18 PhD students / 7 Master students
European Institute of Oncology (IEO) and Hunimed, Milan

Former students and postdocs (selected):

- Luca Giorgetti (PhD 2006-2010 at IEO; now PI at FMI, Basel, Switzerland. ERC starting grant and SNSF consolidator grant winner; EMBO Young Investigator and EMBO member)
- Ivan Marazzi (PhD 2003-2005 at IRB; now PI at Mount Sinai, New York, USA)
- Renato Ostuni (postdoc 2011-2015 at IEO; now PI at DIBIT, San Raffaele Clinical Research Hospital, Milan. ERC starting and ERC consolidator grant winner)
- Francesca De Santa (postdoc 2005-2010 at IEO; now PI, National Research Council, CNR, Rome, Italy)
- Simona Saccani (postdoc 2000-2005 at IRB; now PI at the Institute for Research on Cancer, IRCAN, Nice, France)
- Iros Barozzi (PhD 2009-2014 at IEO; postdoc at Lawrence Berkeley National Laboratory, Berkeley, USA; Research Fellow at the Imperial College, London; now PI at Vienna University, Austria)
- Betsabeh Khoramian Tusi: PhD student 2007-2011; postdoc at Harvard Medical School; now Senior Scientist at Rubius Therapeutics, Boston, MA.
- Liv M. Austenaa: postdoctoral fellow and staff scientist, 2008-2020; now Senior Scientist at Eleven Therapeutics, Cambridge, UK.
- Marta Milan: PhD student 2017-2021; now postdoc at the Crick Institute, London, UK.

SELECTED PUBLICATIONS

An integrative epigenome-based strategy for unbiased functional profiling of clinical kinase inhibitors. (Gualdrini F, Rizzieri S, Polletti S, Pileri F, Zhan Y, Cuomo A, Natoli G.)
Molecular Systems Biology 2024 May 9. doi: 10.1038/s44320-024-00040-x. Epub ahead of print. PMID: 38724853.

Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer (Cortesi A, Gandolfi F, Arco F, Di Chiaro P, Valli E, Polletti S, Noberini R, Gualdrini F, Attanasio S, Citron F, Ho IL, Shah R, Yen EY, Spinella MC, Ronzoni S, Rodighiero S, Mitro N, Bonaldi T, Ghisletti S, Monticelli S, Viale A, Diaferia GR, Natoli G.)
Science Advances. 2024 Mar 29;10(13):eadk5386. doi: 10.1126/sciadv.adk5386. Epub 2024 Mar 27. PMID: 38536927

Mapping functional to morphological variation reveals the basis of regional extracellular matrix subversion and nerve invasion in pancreatic cancer (Di Chiaro P, Nacci L, Arco F, Brandini S, Polletti S, Palamidessi A, Donati B, Soriani C, Gualdrini F, Frigè G, Mazzarella L, Ciarrocchi A, Zerbi A, Spaggiari P, Scita G, Rodighiero S, Barozzi I, Diaferia GR, Natoli G.)
Cancer Cell. 2024 Apr 8;42(4):662-681.e10. doi: 10.1016/j.ccell.2024.02.017. Epub 2024 Mar 21. PMID: 38518775

Acetyl-CoA production by Mediator-bound 2-ketoacid dehydrogenases boosts de novo histone acetylation and is regulated by nitric oxide (Russo M., Gualdrini F., Prosperini E., Noberini R., Pedretti S., Vallelonga V., Di Chiaro P., Polletti S., Ghirardi C., Bedin F., Cuomo A., Rodighiero S., Bonaldi T., Mitro N., Ghisletti S., Natoli G.)
Molecular Cell Mar 7;84(5):967-980.e10. doi: 10.1016/j.molcel.2023.12.033. Epub 2024 Jan 18. PMID: 38242130

Cancer evolution: a multifaceted affair (Ciriello G., Magnani L., Aitken S., Akkari L., Behjati S., Hanahan D., Landau D., López-Bigas N., Lupiáñez D., Marine J.C., Martin-Villalba A., Natoli G, Obenauf A., Oricchio E., Scaffidi P., Sottoriva A, Swarbrick A, Tonon G., Vanharanta S., and Zuber J.)
Cancer Discovery Dec 6:OF1-OF13. doi: 10.1158/2159-8290.CD-23-0530 (Online ahead of print) PMID: 38047596

Restrictor synergizes with Symplekin and PNUTS to terminate extragenic transcription (Russo M., Piccolo V., Polizzese D., Prosperini E., Borriero C., Polletti S., Bedin F., Marenda M., Michieletto D., Mandana G.M., Rodighiero S., Cuomo A., Natoli G.)
Genes & Development Dec 26, 37(21-24):1017-1040. doi: 10.1101/gad.351057.123 (Online ahead of print). PMID: 38092518 (2023)

Interferon regulatory factor 1 (IRF1) controls the metabolic programmes of low-grade pancreatic cancer cells. (Alfarano G, Audano M, Di Chiaro P, Balestrieri C, Milan M, Polletti S, Spaggiari P, Zerbi A, Diaferia GR, Mitro N, Natoli G.)
Gut. 2023 Jan;72(1):109-128. doi: 10.1136/gutjnl-2021-325811. Epub 2022 May 13. PMID: 35568393.

Current challenges in understanding the role of enhancers in disease (Zaugg J., Sahlen P., Andersson R., Alberich-Jorda M., de Laat W., Deplancke B., Ferrer J., Mandrup S., Natoli G., Plewczynski D., Rada-Iglesias A., Spicuglia S.)
Nature Structural and Molecular Biology, 29(12):1148-1158. doi: 10.1038/s41594-022-00896-3. Epub 2022 Dec 8. https://doi.org/10.1038/s41594-022-00896-3. PMID: 36482255 (2022)

Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection (Pileri F, Natoli G.)
Trends Immunol. Sep;43(9):693-695. doi: 10.1016/j.it.2022.07.009. PMID: 35945112 (2022)

H3K9 trimethylation in active chromatin restricts the usage of functional CTCF sites in SINE B2 repeats (Gualdrini F, Polletti S, Simonatto M, Prosperini E, Pileri F, Natoli G)
Genes & Development Apr 1;36(7-8):414-432. doi: 10.1101/gad.349282.121. PMID: 35361678 (2022)

RFX transcription factors control a miR-150/PDAP1 axis that restrains the proliferation of human T cells. (Chirichella M, Bianchi N, Džafo E, Foli E, Gualdrini F, Kenyon A, Natoli G, Monticelli S.)
PLoS Biol. Feb 10;20(2):e3001538. doi: 10.1371/journal.pbio.3001538. PMID: 35143476 (2022)

Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. (Del Poggetto E, Ho IL, Balestrieri C, Yen EY, Zhang S, Citron F, Shah R, Corti D, Diaferia GR, Li CY, Loponte

S, Carbone F, Hayakawa Y, Valenti G, Jiang S, Sapio L, Jiang H, Dey P, Gao S, Deem AK, Rose-John S, Yao W, Ying H, Rhim AD, Genovese G, Heffernan TP, Maitra A, Wang TC, Wang L, Draetta GF, Carugo A, Natoli G, Viale A)
Science Sep 17;373(6561):eabj0486. doi: 10.1126/science.abj0486. PMID: 34529467 (2021)

Integration of transcriptional and metabolic control in macrophage activation (Natoli G, Pileri F, Gualdrini F, Ghisletti S.)
EMBO Rep. Sep 6;22(9):e53251. doi: 10.15252/embr.202153251PMID: 34328708 (2021)

ADP-ribosyltransferases, an update on function and nomenclature (Lüscher B, Ahel I, Altmeyer M, Ashworth A, Bai P, Chang P, Cohen M, Corda D, Dantzer F, Daugherty MD, Dawson TM, Dawson VL, Deindl S, Fehr AR, Feijs KLH, Filippov DV, Gagné JP, Grimaldi G, Guettler S, Hoch NC, Hottiger MO, Korn P, Kraus WL, Ladurner A, Lehtiö L, Leung AKL, Lord CJ, Mangerich A, Matic I, Matthews J, Moldovan GL, Moss J, Natoli G, Nielsen ML, Niepel M, Nolte F, Pascal J, Paschal BM, Pawłowski K, Poirier GG, Smith S, Timinszky G, Wang ZQ, Yélamos J, Yu X, Zaja R, Ziegler M)
FEBS J. Jul 29. doi: 10.1111/febs.16142. Epub ahead of print. PMID: 34323016 (2021)

Induction of OCT2 contributes to regulate the gene expression program in human neutrophils activated via TLR8. (Tamassia N, Bianchetto-Aguilera F, Gasperini S, Polletti S, Gardiman E, Ostuni R, Natoli G, Cassatella MA)
Cell Reports May 18;35(7):109143. doi: 10.1016/j.celrep.2021.109143. PMID: 34010659 (2021)

Tumor cell heterogeneity and its transcriptional bases in pancreatic cancer: a tale of two cell types and their many variants (M. Milan, G.R. Diaferia, G. Natoli)
The EMBO Journal Apr 12:e107206. Jul 1;40(13):e107206. doi: 10.15252/embj.2020107206 (2021)

A first exon termination checkpoint preferentially suppresses extragenic transcription (L. Austenaa, V. Piccolo, M. Russo, E. Prosperini, S. Polletti, D. Polizzese, S. Ghisletti, I. Barozzi, G.R. Diaferia, G. Natoli)
Nature Structural and Molecular Biology 28(4):337-346. PMID: 33767452 (2021).

Pancreatic cancer cells require the transcription factor MYRF (Myelin Regulatory Factor) to maintain ER homeostasis (M. Milan, C. Balestrieri, G. Alfarano, S. Polletti, E. Prosperini, P. Nicoli, P. Spaggiari, A. Zerbi, G.R. Diaferia, G. Natoli)
Developmental Cell 55(4):398-412. PMID: 32997974 (2020).

A molecular network regulating the proinflammatory phenotype of human memory T lymphocytes (Emming S, Bianchi N, Polletti S, Balestrieri C, Leoni C, Montagner S, Chirichella M, Delaleu N, Natoli G, Monticelli S.)
Nature Immunology. 4:388-399. PMID: 32205878 (2020)

Tumor-derived prostaglandin E2 promotes p50 NF-κB-dependent differentiation of monocytic MDSC (Porta C, Consonni FM, Morlacchi S, Sangaletti S, Bleve A, Totaro MG, Larghi P, Rimoldi M, Tripodo C, Strauss L, Banfi S, Storto M, Pressiani T, Rimassa L, Tartari S, Ippolito A, Doni A, Soldà G, Duga S, Piccolo V, Ostuni R, Natoli G, Bronte V, Balzac F, Turco E, Hirsch E, Colombo MP, Sica A.)
Cancer Research 80(13):2874-2888. PMID: 32265223 (2020)

FOXA2 controls the cis-regulatory networks of pancreatic cancer cells in a differentiation grade-specific manner (Milan M., Balestrieri C., Alfarano G., Polletti S., Prosperini E., Spaggiari P., Zerbi A., Diaferia G., Natoli G.)
The EMBO Journal 38(20):e102161 (2019).

Transcriptional repressors as guardians of tissue macrophage identity (Gualdrini F, Natoli G.)
The EMBO Journal 38(19):e103271. PMID: 31529710 (2019)

Dissection of acute stimulus-induced nucleosome remodeling in mammalian cells (Comoglio F., Simonatto M., Polletti S., Liu X., Smale S.T., Barozzi I., Natoli G.)
Genes & Development 33: 1159-1174. PMID: 31371436 (2019)

Adaptation and memory in immune responses (Natoli G. and Ostuni R.) **Nature Immunology** Jul;20(7):783-792. PMID: 31213714 (2019)

Big data in IBD: a look into the future (Olivera P., Danese S. Jay N., Natoli G., Peyrin-Biroulet L.)
Nature Reviews Gastroenterol. Hepatol. 16(5):312-321. PMID: 30659247 (2019)

Control of inducible gene expression links cohesin to hematopoietic progenitor self-renewal and differentiation (Cuartero S, Weiss FD, Dharmalingam G, Guo Y, Ing-Simmons E, Masella S, Robles-Rebollo I, Xiao X,

Wang YF, Barozzi I, Djeghloul D, Amano MT, Niskanen H, Petretto E, Dowell RD, Tachibana K, Kaikkonen MU, Nasmyth KA, Lenhard B, Natoli G, Fisher AG, Merkenschlager M.).
Nature Immunology 19, 932-941. PMID: 30127433 (2018).

Cooptation of tandem DNA repeats for the maintenance of mesenchymal identity (C. Balestrieri, G. Alfarano, M. Milan, V. Tosi, E. Prosperini, P. Nicoli, A. Palamidessi, G. Scita, G.R. Diaferia, G. Natoli).
Cell 173:1150-1164. PMID: 29706544 (2018).

Sustained activation of detoxification pathways promotes liver carcinogenesis in response to chronic bile acid-mediated damage (Collino A, Termanini A, Nicoli P, Diaferia G, Polletti S, Recordati C, Castiglioni V, Caruso D, Mitro N, Natoli G, Ghisletti S.)
PLoS Genetics. 2018, 7;14(5):e1007380. PMID: 29734330 (2018).

PARP14 Controls the Nuclear Accumulation of a Subset of Type I IFN-Inducible Proteins (Caprara G, Prosperini E, Piccolo V, Sigismondo G, Melacarne A, Cuomo A, Boothby M, Rescigno M, Bonaldi T, Natoli G).
Journal of Immunology 200, 2439-2454. PMID 29500242 (2018)

Transcriptional determination and functional specificity of myeloid cells: making sense of diversity (Monticelli S., Natoli G.)
Nature Reviews Immunology 17, 595-607 (2017)

Understanding spontaneous conversion: the case of the Ly6C- monocyte (Polletti S. and Natoli G.).
Immunity 46, 746-766. PMID 28514680 (2017)

Opposing macrophage polarization programs show extensive epigenomic and transcriptional cross-talk (Piccolo V., Curina A, Genua M, Ghisletti S, Simonatto M, Sabo' M, Amati B, Ostuni R, Natoli G).
Nature Immunology 18, 530-540. PMID 28288101 (2017).

High constitutive activity of a broad panel of housekeeping and tissue-specific cis-regulatory elements depends on a subset of ETS proteins (Curina A, Termanini A, Barozzi I, Prosperini E, Simonatto M, Polletti S, Silvola A, Soldi M, Austenaa L, Bonaldi T, Ghisletti S, Natoli G)
Genes & Development 31,399-412. PMID 28275002. (2017).

A shortcut for early macrophage recruitment into tumors by activated oncogenes (Austenaa L, Natoli G)
Genes & Development 31, 223-225; doi: 10.1101/gad.296905.117. Review. PMID 28270513. (2017).

Mutual epithelium-macrophage dependency in liver carcinogenesis mediated by ST18 (Ravà M, D'Andrea A, Doni M, Kress TR, Ostuni R, Bianchi V, Morelli MJ, Collino A, Ghisletti S, Nicoli P, Recordati C, Iascone M, Sonzogni A, D'Antiga L, Shukla R, Faulkner GJ, Natoli G, Campaner S, Amati B.).
Hepatology Nov 14 [Epub ahead of print] PMID 27859418. (2016).

Specificity and Function of IRF Family Transcription Factors: Insights from Genomics (Mancino A, Natoli G.)
J Interferon Cytokine Res. 36:462-9. PMID 27379868. (2016)

In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype (Bossi D, Cicalese A, Dellino GI, Luzi L, Riva L, D'Alesio C, Diaferia GR, Carugo A, Cavallaro E, Piccioni R, Barberis M, Mazzarol G, Testori A, Punzi S, Pallavicini I, Tosti G, Giacó L, Melloni G, Heffernan TP, Natoli G, Draetta GF, Minucci S, Pelicci P, Lanfrancone L.)
Cancer Discovery Jun;6(6):650-63. PMID: 27179036. (2016)

TET2 Regulates Mast Cell Differentiation and Proliferation through Catalytic and Non-catalytic Activities (Montagner S, Leoni C, Emming S, Della Chiara G, Balestrieri C, Barozzi I, Piccolo V, Togher S, Ko M, Rao A, Natoli G, Monticelli S).
Cell Reports, 15, 1566-79. PMID: 27160912. (2016)

Epigenetic regulation of neutrophil development and function (Ostuni R, Natoli G, Cassatella MA, Tamassia N)
Seminars in Immunology 28:83-93. PMID: 27084194. (2016)

Trained immunity: a program of innate immune memory in health and disease (M.G. Netea, L.A.B. Joosten, E. Latz, K.H.G. Mills, G. Natoli, H. Stunnenberg, L.A.J O'Neill, R.J. Xavier)
Science 352(6284):aaf1098. PMID: 27102489. (2016)

From the beauty of genomic landscapes to the strength of transcriptional mechanisms (G. Natoli)
Cell (165, 18-18. PMID: 27015303. (2016).

Dissection of transcriptional and *cis*-regulatory control of differentiation in human pancreatic cancer (G. Diaferia, C. Balestrieri, E. Prosperini, P. Nicoli, P. Spaggiari, A. Zerbi, G. Natoli).
The EMBO Journal 35, 596-617 PMID: 26769127 (2016).

Molecular control of macrophage activation and priming (C.K. Glass and G. Natoli)
Nature Immunology 17, 26-33. PMID: 26681459. (2016)

CAGE profiling of ncRNAs in hepatocellular carcinoma reveals widespread activation of retroviral LTR promoters in virus-induced tumors. (Hashimoto K, Suzuki AM, Dos Santos A, Desterke C, Collino A, Ghisletti S, Braun E, Bonetti A, Fort A, Qin XY, Radaelli E, Kaczkowski B, Forrest AR, Kojima S, Samuel D, Natoli G, Buendia MA, Faivre J, Carninci P.)
Genome Research 25:1812-24. PMID: 26510915. (2015)

Transcription of mammalian cis-regulatory elements is restrained by actively enforced early termination (L. M.I. Austenaa, I. Barozzi, M. Simonatto, S. Masella, G. Della Chiara, S. Ghisletti, A. Curina, E. de Wit, B.A.M. Bouwman, S. de Pretis, V. Piccolo, A. Termanini, E. Prosperini, M. Pelizzola, W. de Laat, and G. Natoli).
Molecular Cell 60, 460-474. PMID: 26593720. (2015).

Macrophages and cancer: from mechanisms to therapeutic implications (R. Ostuni, F. Kratochvill, P.J. Murray, G. Natoli)
Trends in Immunology 36, 229-239. PMID: 25770924. (2015).

A dual *cis*-regulatory code links IRF8 to constitutive and inducible gene expression in macrophages (A. Mancino, A. Termanini, I. Barozzi, S. Ghisletti, R. Ostuni, E. Prosperini, K. Ozato, G. Natoli)
Genes & Development 29, 394-408. PMID: 25637355. (2015).

Chromatin remodelling and autocrine TNFα are required for optimal interleukin-6 expression in activated human neutrophils. (Zimmermann M, Aguilera FB, Castellucci M, Rossato M, Costa S, Lunardi C, Ostuni R, Girolomoni G, Natoli G, Bazzoni F, Tamassia N, Cassatella MA.)
Nature Commun. 2015 6:6061. PMID: 25616107. (2015).

Co-regulation of transcription factor binding and nucleosome occupancy through DNA features of mammalian enhancers (I. Barozzi, M. Simonatto, S. Bonifacio, L. Yang, R. Rohs, S. Ghisletti, G. Natoli)
Molecular Cell 54, 844-857. PMID: 24813947. (2014).

Transcriptional control of inflammatory responses (S.T. Smale, G. Natoli)
Cold Spring Harb Perspect Biol. 6(11):a016261. PMID: 25213094. (2014).

Macrophage activation: glancing into diversity (G. Natoli, S. Monticelli)
Immunity 40:175-7. PMID: 24560195. (2014).

Two functionally distinct subsets of mast cells discriminated by IL-2-independent CD25 activities (Deho' L, Leoni C, Brodie TM, Montagner S, De Simone M, Polletti S, Barozzi I, Natoli G, Monticelli S.)
J Immunol.
193:2196-206. PMID: 25063866. (2014)

Macrophage activation and polarization: nomenclature and experimental guidelines (Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G., Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA.)
Immunity 41:14-20. PMID: 25035950. (2014).

Chromatin contribution to the regulation of innate immunity (S. Smale, A. Tharakovsky, G. Natoli)
Annual Review of Immunology 32: 489-511. PMID: 24555473 (2014).

Massive gene amplification drives paediatric hepatocellular carcinoma caused by bile salt export pump deficiency (Iannelli F, Collino A, Sinha S, Radaelli E, Nicoli P, D'Antiga L, Sonzogni A, Faivre J, Buendia MA, Sturm E, Thompson RJ, Knisely AS, Natoli G, Ghisletti S, Ciccarelli FD.)
Nature Comm. 5:3850-3856 PMID: 24819516. (2014).

Lineages, cell types and functional states: a genomic view (R. Ostuni and G. Natoli)
Curr. Opin. Cell. Biol. 25(6):759-64. PMID: 23906851. (2013).

Short term memory of danger signals and environmental stimuli in immune cells. (S. Monticelli and G. Natoli).
Nature Immunol. 14, 777-784. PMID: 23867934. (2013).

Non-coding transcription at cis-regulatory elements: computational and experimental approaches (Simonatto M, Barozzi I, Natoli G).
Methods 63:66-75. (2013).

Cutting edge: An inactive chromatin configuration at the IL-10 locus in human neutrophils (Tamassia N, Zimmermann M, Castellucci M, Ostuni R, Bruderek K, Schilling B, Brandau S, Bazzoni F, Natoli G, Cassatella MA.)
J Immunol. 190:1921-5 (2013).

Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma (Shukla R, Upton K, Muñoz-Lopez M, Gerhardt D, Fisher M, Nguyen T, Brennan T, Baillie T, Collino A, Ghisletti S, Sinha S, Iannelli F, Radaelli F, Dos Santos A, Rapoud D, Guettier C, Samuel D, Natoli G, Carninci P, Ciccarelli F, Garcia-Perez JC, Faivre J, Faulkner G.)
Cell 153:101-11 (2013)

Latent enhancers activated by stimulation in differentiated cells (Ostuni R, Piccolo V, Barozzi I, Polletti S, Termanini A, Bonifacio S, Curina A, Prosperini E, Ghisletti S, Natoli G.)
Cell. 152: 157-71. PMID: 23332752 (2013).

The H3K27 Demethylase JMJD3 Is Required for Maintenance of the Embryonic Respiratory Neuronal Network, Neonatal Breathing, and Survival (Burgold T, Voituron N, Caganova M, Tripathi PP, Menuet C, Tusi BK, Spreafico F, Bvengut M, Gestreau C, Buontempo S, Simeone A, Kruidenier L, Natoli G, Casola S, Hilaire G, Testa G.)
Cell Reports 2:1244-58 (2012).

Requirement for the histone deacetylase HDAC3 for the inflammatory gene expression program (X. Chen, I. Barozzi, A. Termanini, E. Prosperini, A. Recchiuti, J. Dalli, F. Mietton, G. Matteoli, S. Hiebert, G. Natoli)
Proc Natl Acad Sci USA 109:E2865-74 (2012)

Noncoding transcription at enhancers: general principles and functional models (G. Natoli and J.C. Andrau)
Annual Review of Genetics 46:1-19. PMID: 22905871 (2012).

Transcript dynamics of pro-inflammatory genes uncovered by RNA-Seq analysis of subcellular RNA fractions. (D.M. Bhatt, A. Pandya-Jones, A.J. Tong, I. Barozzi, M. Lissner, G. Natoli, Black D.L., Smale S.T.)
Cell 150, 279-290 (2012).

The histone methyltransferase Mll4 controls macrophage function through glycosylphosphatidylinositol anchor synthesis (L. Austenaa, I. Barozzi, A. Chronowska, A. Termanini, R. Ostuni, E. Prosperini, A. F. Stewart, G. Testa, G. Natoli)
Immunity 36, 572-585 (2012).

NF-κB and chromatin: ten years on the path from basic mechanisms to candidate drugs. (G. Natoli)
Immunological Reviews 246, 183-192 (2012).

Transcriptional control of macrophage polarization: enabling diversity with identity (T. Lawrence, G. Natoli)
Nature Reviews Immunology 11, 750-761. PMID: 22025054 (2011).

Fish the ChIPs: a pipeline for automated genomic annotation of ChIP-Seq data (I. Barozzi, A. Termanini, S. Minucci, G. Natoli)
Biology Direct 6:51 (2011).

Transcriptional control of macrophage diversity and specialization (R. Ostuni and G. Natoli).
Eur. J. Immunol. 41, 2486-90 (2011).

The genomic landscapes of inflammation (G. Natoli, S. Ghisletti, I. Barozzi)
Genes & Development 25, 101-106 (2011).

Specialized Chromatin Patterns in the Control of Inflammatory Gene Expression (G. Natoli)
Curr Top Microbiol Immunol. 2010 Sep 21. [Epub ahead of print]

Maintaining cell identity through global control of genomic organization (G. Natoli).
Immunity 23:12-24. PMID: 20643336 (2010).

A large fraction of extragenic RNA Pol II transcription sites overlap enhancers (F. De Santa, I. Barozzi, F. Mietton, S. Ghisletti, S. Polletti, BK Tusi, H. Muller, J. Ragoussis, CL Wei, G. Natoli)
PLoS Biology 8(5): e1000384. doi:10.1371/journal.pbio.1000384 (2010).

Identification and characterization of enhancers controlling the inflammatory gene expression program in macrophages (S. Ghisletti, I. Barozzi, F. Mietton, S. Polletti, F. De Santa, E. Venturini, L. Gregory, L. Lonie, A. Chew, C.L. Wei, J. Ragoussis, G. Natoli)
Immunity, 32:317-28. Epub 2010 Mar 4 (2010).

Non-cooperative interactions between transcription factors and clustered DNA binding sites enable graded transcriptional responses to environmental inputs (L. Giorgetti, T. Siggers, G. Tiana, G. Caprara, S. Notarbartolo, T. Corona, M. Pasparakis, P. Milani, M. L. Bulyk, G. Natoli).
Molecular Cell 37, 418-428 (2010)

Jmjd3 contributes to the control of gene expression in LPS-activated macrophages (F. De Santa, V. Narang, Z. H. Yap, B. Khoramian Tusi, T.Burgold, L. Austenaa, G. Bucci, M. Caganova, S. Notarbartolo, S. Casola, G. Testa, WK. Sung, CL. Wei, and G. Natoli).
The EMBO J. 28, 3341-52 (2009).

Control of NF-kappaB-dependent Transcriptional Responses by Chromatin Organization (G. Natoli).
Cold Spring Harbor Perspect Biol. Oct;1(4):a000224. (2009)

The future therapeutic potential of histone demethylase inhibitors: a critical analysis. (G. Natoli, G. Testa, F. De Santa).
Curr. Opin. Drug. Devel. & Discov. 12, 607-615 (2009).

Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor {kappa}B. (Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, Di Liberto D, Dieli F, Ghisletti S, Natoli G, De Baetselier P, Mantovani A, Sica A.).
Proc Natl Acad Sci USA 106:14978-83. Epub 2009 Aug 17 (2009).

Chromatin-mediated control of gene expression in innate immunity and inflammation (G. Natoli).
Handbook of Cell Signalling 2nd edition. (Bradshaw and Dennis eds., Academic Press) pp. 2461-2466 (2009).

Genome-Organizing Factors Top2 and Hmo1 Prevent Chromosome Fragility at Sites of S phase Transcription (R. Bermejo, T. Capra, V. Gonzalez-Huici, D. Fachinetti, A. Cocito, G. Natoli, Y. Katou, H. Mori, K. Kurokawa, K.Shirahige and M. Foiani)
Cell 138, 870-884 (2009).

Two modes of transcriptional activation at native promoters by NF-kappaB p65 (van Essen D, B. Engist , G. Natoli, Saccani S)
PLoS Biol. 7(3):e73 (2009).

When sirtuins and NF-kB collide (G. Natoli)
Cell 136, 19-21 (2009).

A birthday gift for TRADD. (G. Natoli and L. Austenaa).
Nature Immunol. 9, 1015-6 (2008).

Burgold T, Spreafico F, De Santa F, Totaro MG, Prosperini E, Natoli G, Testa G. The histone H3 lysine 27-specific demethylase Jmjd3 is required for neural commitment.
PLoS ONE. 2008 Aug 21;3(8):e3034.

Nuclear ubiquitin ligases, NF-kB degradation and the control of inflammation (G. Natoli and S. Chiocca).
Science Signaling, January 8, pe1 (2008).

The histone H3 lysine 27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing (F. De Santa, M.G. Totaro, E. Prosperini, S. Notarbartolo, G. Testa and G. Natoli).
Cell 130, 1083-1094 (2007).

Natoli G. Tuning up inflammation: how DNA sequence and chromatin organization control the induction of inflammatory genes by NF-kappaB.
FEBS Lett. 580:2843-9 (2006).

A hyper-dynamic equilibrium between promoter-bound and nucleoplasmic dimers controls NF-kB-dependent gene activity (D. Bosisio, I. Marazzi, A. Agresti, N. Shimizu, M.E. Bianchi and G. Natoli).
The EMBO J. 25, 798-810 (2006).

Transcriptional regulation via the NF-kappaB signaling module (Hoffmann A, Natoli G, Ghosh G)
Oncogene. 30, 6706-16 (2006).

A c-Rel subdomain responsible for enhanced DNA-binding activity and selective gene activation (S. Sanjabi, KJ. Williams, S. Saccani, L. Zhou, A. Hoffmann, G. Ghosh, S. Gerondakis, D. Baltimore, G. Natoli and S.T. Smale)
Genes & Development 19, 2138-2151 (2005).

Interactions of NF-kB with chromatin: the art of being at the right place at the right time (G. Natoli, S. Saccani, D. Bosisio, I. Marazzi).
Nature Immunol. 6, 439-445 (2005).

Arginine methyltransferase CARM1 is a promoter-specific regulator of NF-kB-dependent gene expression (M. Covic, PO. Hassa, S. Saccani, C. Buerki, N.I. Meier, C. Lombardi, R. Imhof, M.T. Bedford, G. Natoli, MO. Hottiger).
The EMBO J. 24, 85-96 (2005).

Little things that count in transcriptional regulation (G. Natoli)
Cell 118, 406-408 (2004).

Degradation of promoter-bound p65/RelA is essential for the prompt termination of the NF-kB response (S. Saccani, I. Marazzi, G. Natoli)
J. Exp. Med. 200, 107-113 (2004)

Modulation of NF-kB activity by exchange of dimers (S. Saccani, S. Pantano, G. Natoli)
Molecular Cell 11, 1563-1574 (2003).

Memory and flexibility of cytokine gene expression as separable properties of human Th1 and Th2 lymphocytes (M. Messi, I. Giachetto, K. Nagata, A. Lanzavecchia, G. Natoli and F. Sallusto).
Nature Immunol. 4, 78-86 (2003).

Dynamic changes in histone H3-Lys9 methylation occurring at tightly regulated inducible inflammatory genes (S. Saccani and G. Natoli).
Genes & Development 16, 2219-2214 (2002).

p38-dependent marking of inflammatory genes for increased Nuclear Factor kappa B recruitment (S. Saccani, S.Pantano, G.Natoli).
Nature Immunol. 3, 69-75 (2002).

Two waves of Nuclear Factor kappa B recruitment to target promoters. (S.Saccani, S.Pantano, G. Natoli).
J. Exp. Med. 193, 1351-1359 (2001).

Anti-inflammatory cyclopentenons prostaglandins are direct inhibitors of IkB kinase (IKK) (A. Rossi*, P. Kapahi*, G. Natoli*, T. Takahashi, Y. Chen, M. Karin*, G. Santoro*)
Nature 403, 103-108 (2000) * *equal contributors*

IKK gamma is an essential regulatory subunit of the IkB kinase complex (D. Rothwarf, E. Zandi, G. Natoli, M. Karin)
Nature 395, 297-300 (1998).

The human Toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6) (M. Muzio, G. Natoli, S. Saccani, M. Levrero, A. Mantovani).
J. Exp. Med. 187, 2097-2101 (1998).

Activation of SAPK/JNK by TNF-Receptor 1 through a non-cytotoxic TRAF2-dependent pathway (G. Natoli, A. Costanzo, A. Ianni, D.J. Templeton, J.R. Woodgett, C. Balsano, M. Levrero)
Science 275, 200-203 (1997).

The hepatitis B virus X gene induces p53-mediated programmed cell death (P. Chirillo, S. Pagano, G.Natoli, P.L. Puri, V.L. Burgio, C. Balsano, M. Levrero)
Proc. Natl. Acad. Sci. *USA* 94, 8162-8167 (1997).

Hepatitis B virus pX activates NFkB dependent transcription through a Raf-independent pathway (P. Chirillo, M. Falco, P.L. Puri, M. Artini, C. Balsano, M. Levrero, G. Natoli)
Journal of Virology 70, 1, 641-646 (1996).

Resistance to Fas-mediated apoptosis in human hepatoma cells (G. Natoli, A. Ianni, A. Costanzo, G. De Petrillo, I. Ilari, P. Chirillo, C. Balsano, M. Levrero).
Oncogene 11, 1157-1164 (1995).

Modulation of intracellular signal transduction pathways by the hepatitis B virus transactivator pX (G. Natoli, M.L. Avantaggiati, P. Chirillo, E. De Marzio, D. Collepardo, M. Falco, C. Balsano, M. Levrero).
Journal of Hepatology Supp 22, 14-20 (1995).

Induction of the c-Jun/c-Fos heterodimers DNA binding activity by the hepatitis B virus transactivator pX. (G. Natoli, M.L. Avantaggiati, P. Chirillo, A. Costanzo, M. Artini, C. Balsano, M. Levrero).
Molecular and Cellular Biology 14, 989-998 (1994).

Expression of the c-Myc proto-oncogene in cells infected with Hepatitis Delta Virus. (G. Tappero, G. Natoli, G. Anfossi, F. Rosina, F. Negro, A. Smedile, F. Bonino, A. Angeli, R. H. Purcell, M. Rizzetto, M. Levrero).
Hepatology 20, 1109-1114 (1994).

Ras- and Raf-dependent induction of c-Jun transcriptional activity by the Hepatitis B Virus transactivator pX. (G. Natoli, M.L. Avantaggiati, P. Chirillo, P.L. Puri, C. Balsano, M. Levrero).
Oncogene 9, 2837-2843 (1994).

The Hepatitis B Virus pX transactivates the c-Fos promoter through multiple cis-acting elements. (M.L. Avantaggiati, G. Natoli, C. Balsano, P. Chirillo, M. Artini, E. De Marzio, D. Collepardo, M. Levrero).
Oncogene 8, 1567-1574 (1993).

Characterization of the Hepatitis B Virus preS/S region encoded transcriptional transactivator. (G. Natoli, M.L. Avantaggiati, C. Balsano, E. De Marzio, D. Collepardo, E. Elfassi, M. Levrero).
Virology 187, 663-670 (1992).

Defective and non-defective adenovirus vectors to express foreign genes in vitro and in vivo (M. Levrero, V. Barbant, A. Ballay, C. Balsano, M.L. Avantaggiati, G. Natoli, H. Skellens, P. Tiollais, M. Perricaudet).
Gene 45, 342-342-350 (1991).

The hepatitis B virus X protein transactivates the long terminal repeats of human immunodeficiency virus types 1 and 2 (M. Levrero, C. Balsano, G. Natoli, M.L. Avantaggiati, E. Elfassi).
Journal of Virology 64, 3082-3086 (1990).